


CLAIMS

- 5 1. A pharmaceutical composition comprising a therapeutically effective amount of an Active Pharmaceutical Ingredient, a β -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.
- 10 2. A pharmaceutical composition according to claim 1 wherein the Active Pharmaceutical Ingredient is a compound of Formula I,



or its pharmaceutically acceptable salts, wherein R^2 is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.

- 15 3. The pharmaceutical composition according to Claims 1 or 2 wherein the β -cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or sulfobutyl ether- β -cyclodextrin.
4. The pharmaceutical composition according to any preceding claim wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol or a combination thereof.

5. The pharmaceutical composition according to any preceding claim wherein the preservative has a binding value to the cyclodextrin that is less than a binding value of the Active Pharmaceutical Ingredient to cyclodextrin.
6. The pharmaceutical composition according to any preceding claim
- 5 wherein about 1 mg/mL to about 5 mg/mL of the preservative is unsequestered in the cyclodextrin.
7. The pharmaceutical composition according to any preceding claim wherein the binding value of the Active Pharmaceutical Ingredient to cyclodextrin is between 500 M^{-1} and $10,000 \text{ M}^{-1}$.
- 10 8. The pharmaceutical composition according to any preceding claim for use as a medicament.
9. The use of a composition according to any of Claims 2 to 7 in the manufacture of a medicament for the treatment of a disease for which a neurokinin receptor antagonist is indicated.
- 15 10. A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of any of Claims 2 to 7.